

Cover Story
Guest Editorial
At a recent NIH study section that I chaired, we had many applications that we reviewed as a group before the meeting. At the meeting, we were required to discuss over 50% of the grants.
By Claire Dietz and Matthew Bin Han Ong
Conversation with The Cancer Letter
By Matthew Bin Han Ong and Claire Dietz
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
NCI Trials


NCI Trials for July
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- NIH Director Jay Bhattacharya launches a podcast
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention
- “Forward funding” NIH budget plan would make competing for grants much harder
- Optimizing dosing of expensive and toxic oncology drugs: Making America healthier
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”